The global antinuclear antibody (ANA) test market is poised for substantial growth, with market valuation expected to rise from USD 2.10 billion in 2025 to USD 6.48 billion by 2034, expanding at a robust CAGR of 13.38% during the forecast period. This growth is primarily fueled by the increasing integration of expanded autoantibody panels into routine clinical workflows, enabling...
SPARK Website
English